Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias

doi:10.1056/NEJMoa055229

Volume 354:2531-2541		June 15, 2006		Number 24

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz, M.D., Neil P. Shah, M.D., Ph.D., Hagop Kantarjian, M.D., Nicholas Donato, Ph.D., John Nicoll, B.A., Ron Paquette, M.D., Jorge Cortes, M.D., Susan O'Brien, M.D., Claude Nicaise, M.D., Eric Bleickardt, M.D., M. Anne Blackwood-Chirchir, M.D., Vishwanath Iyer, M.S., Tai-Tsang Chen, M.Phil., Fei Huang, Ph.D., Arthur P. Decillis, M.D., and Charles L. Sawyers, M.D.

Full Text

PDF

PDA Full Text

PowerPoint Slide Set

Supplementary Material
Video Animation

Letters

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

PubMed Citation

ABSTRACT

Background The BCR-ABL tyrosine kinase inhibitor imatinib iseffective in Philadelphia chromosome–positive (Ph-positive)leukemias, but relapse occurs, mainly as a result of the outgrowthof leukemic subclones with imatinib-resistant BCR-ABL mutations.We evaluated dasatinib, a BCR-ABL inhibitor that targets mostimatinib-resistant BCR-ABL mutations, in patients with chronicmyelogenous leukemia (CML) or Ph-positive acute lymphoblasticleukemia (ALL).

Methods Patients with various phases of CML or with Ph-positiveALL who could not tolerate or were resistant to imatinib wereenrolled in a phase 1 dose-escalation study. Dasatinib (15 to240 mg per day) was administered orally in four-week treatmentcycles, once or twice daily.

Results A complete hematologic response was achieved in 37 of40 patients with chronic-phase CML, and major hematologic responseswere seen in 31 of 44 patients with accelerated-phase CML, CMLwith blast crisis, or Ph-positive ALL. In these two phases,the rates of major cytogenetic response were 45 percent and25 percent, respectively. Responses were maintained in 95 percentof patients with chronic-phase disease and in 82 percent ofpatients with accelerated-phase disease, with a median follow-upmore than 12 months and 5 months, respectively. Nearly all patientswith lymphoid blast crisis and Ph-positive ALL had a relapsewithin six months. Responses occurred among all BCR-ABL genotypes,with the exception of the T315I mutation, which confers resistanceto both dasatinib and imatinib in vitro. Myelosuppression wascommon but not dose-limiting.

Conclusions Dasatinib induces hematologic and cytogenetic responsesin patients with CML or Ph-positive ALL who cannot tolerateor are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov] .)

Source Information

From the Departments of Leukemia (M.T., H.K., J.C., S.O.) and Experimental Therapeutics (M.T., N.D.), M.D. Anderson Cancer Center, Houston; Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles (N.P.S., J.N., R.P., C.L.S.); Bristol-Myers Squibb, Wallingford, Conn. (C.N., E.B., V.I., T.-T.C., A.P.D.), and Lawrenceville, N.J. (M.A.B.-C., F.H.); and Howard Hughes Medical Institute, Chevy Chase, Md. (C.L.S.).

Drs. Talpaz and Sawyers contributed equally to this article.

Address reprint requests to Dr. Sawyers at Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 11-934 Factor Bldg., 10833 LeConte Ave., Los Angeles, CA 90095, or at csawyers{at}mednet.ucla.edu.

Full Text of this Article

Related Letters:

Dasatinib in Chronic Myelogenous Leukemia
Kathula S. K., Chu S.-C., Tang J.-L., Li C.-C., Sawyers C. L., Talpaz M., Bleickardt E.
Extract | Full Text | PDF
N Engl J Med 2006; 355:1062-1064, Sep 7, 2006. Correspondence

This article has been cited by other articles:

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., Clark, R. E. (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112: 3348-3354 [Abstract] [Full Text]
Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., Hazlehurst, L. A. (2008). Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics 7: 3169-3175 [Abstract] [Full Text]
Distler, J. H. W., Distler, O. (2008). Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) 47: v10-v11 [Abstract] [Full Text]
Veldurthy, A., Patz, M., Hagist, S., Pallasch, C. P., Wendtner, C.-M., Hallek, M., Krause, G. (2008). The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 112: 1443-1452 [Abstract] [Full Text]
Frohling, S., Dohner, H. (2008). Chromosomal Abnormalities in Cancer. NEJM 359: 722-734 [Full Text]
Fabarius, A., Giehl, M., Rebacz, B., Kramer, A., Frank, O., Haferlach, C., Duesberg, P., Hehlmann, R., Seifarth, W., Hochhaus, A. (2008). Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. haematol 93: 1145-1154 [Abstract] [Full Text]
Quintas-Cardama, A., Cortes, J. (2008). Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia. Clin. Cancer Res. 14: 4392-4399 [Abstract] [Full Text]
Wu, J., Meng, F., Kong, L.-Y., Peng, Z., Ying, Y., Bornmann, W. G., Darnay, B. G., Lamothe, B., Sun, H., Talpaz, M., Donato, N. J. (2008). Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase. JNCI J Natl Cancer Inst 100: 926-939 [Abstract] [Full Text]
Christopher, L. J., Cui, D., Wu, C., Luo, R., Manning, J. A., Bonacorsi, S. J., Lago, M., Allentoff, A., Lee, F. Y. F., McCann, B., Galbraith, S., Reitberg, D. P., He, K., Barros, A. Jr., Blackwood-Chirchir, A., Humphreys, W. G., Iyer, R. A. (2008). Metabolism and Disposition of Dasatinib after Oral Administration to Humans. Drug Metab. Dispos. 36: 1357-1364 [Abstract] [Full Text]
Shah, N. P., Kantarjian, H. M., Kim, D.-W., Rea, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., Khoroshko, N., Paquette, R. L., Deininger, M., Collins, R. H., Otero, I., Hughes, T., Bleickardt, E., Strauss, L., Francis, S., Hochhaus, A. (2008). Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. JCO 26: 3204-3212 [Abstract] [Full Text]
Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jungel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., Distler, J. H. W. (2008). Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22: 2214-2222 [Abstract] [Full Text]
Jabbour, E., Kantarjian, H., Jones, D., Breeden, M., Garcia-Manero, G., O'Brien, S., Ravandi, F., Borthakur, G., Cortes, J. (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112: 53-55 [Abstract] [Full Text]
Mullighan, C. G., Williams, R. T., Downing, J. R., Sherr, C. J. (2008). Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 22: 1411-1415 [Abstract] [Full Text]
Katsoulas, A., Rachid, Z., McNamee, J. P., Williams, C., Jean-Claude, B. J. (2008). Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Molecular Cancer Therapeutics 7: 1033-1043 [Abstract] [Full Text]
Samudio, I., Kurinna, S., Ruvolo, P., Korchin, B., Kantarjian, H., Beran, M., Dunner, K. Jr., Kondo, S., Andreeff, M., Konopleva, M. (2008). Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Molecular Cancer Therapeutics 7: 1130-1139 [Abstract] [Full Text]
Weichsel, R., Dix, C., Wooldridge, L., Clement, M., Fenton-May, A., Sewell, A. K., Zezula, J., Greiner, E., Gostick, E., Price, D. A., Einsele, H., Seggewiss, R. (2008). Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib. Clin. Cancer Res. 14: 2484-2491 [Abstract] [Full Text]
O'Hare, T., Eide, C. A., Tyner, J. W., Corbin, A. S., Wong, M. J., Buchanan, S., Holme, K., Jessen, K. A., Tang, C., Lewis, H. A., Romero, R. D., Burley, S. K., Deininger, M. W. (2008). SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl. Acad. Sci. USA 105: 5507-5512 [Abstract] [Full Text]
Kenealy, L. K., Christenson, C. B., Williams, C. B. (2008). Current Therapies for Chronic Myeloid Leukemia. Journal of Pharmacy Practice 21: 116-125 [Abstract]
Ramirez, P., DiPersio, J. F. (2008). Therapy Options in Imatinib Failures. The Oncologist 13: 424-434 [Abstract] [Full Text]
Harb, J. G., Chyla, B. I., Huettner, C. S. (2008). Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood 111: 3760-3769 [Abstract] [Full Text]
Wu, J., Meng, F., Lu, H., Kong, L., Bornmann, W., Peng, Z., Talpaz, M., Donato, N. J. (2008). Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111: 3821-3829 [Abstract] [Full Text]
Carayol, N., Katsoulidis, E., Sassano, A., Altman, J. K., Druker, B. J., Platanias, L. C. (2008). Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway. J. Biol. Chem. 283: 8601-8610 [Abstract] [Full Text]
Kneidinger, M., Schmidt, U., Rix, U., Gleixner, K. V., Vales, A., Baumgartner, C., Lupinek, C., Weghofer, M., Bennett, K. L., Herrmann, H., Schebesta, A., Thomas, W. R., Vrtala, S., Valenta, R., Lee, F. Y., Ellmeier, W., Superti-Furga, G., Valent, P. (2008). The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 111: 3097-3107 [Abstract] [Full Text]
Laudadio, J., Deininger, M. W.N., Mauro, M. J., Druker, B. J., Press, R. D. (2008). An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy. J. Mol. Diagn. 10: 177-180 [Abstract] [Full Text]
Fojo, T. (2008). Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better. The Oncologist 13: 277-283 [Full Text]
Copland, M., Pellicano, F., Richmond, L., Allan, E. K., Hamilton, A., Lee, F. Y., Weinmann, R., Holyoake, T. L. (2008). BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111: 2843-2853 [Abstract] [Full Text]
Huang, X.-F., Luo, S.-K., Xu, J., Li, J., Xu, D.-R., Wang, L.-H., Yan, M., Wang, X.-R., Wan, X.-B., Zheng, F.-M., Zeng, Y.-X., Liu, Q. (2008). Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111: 2854-2865 [Abstract] [Full Text]
Mayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J., Ott, R. G., Greish, K., Nakamura, H., Derdak, S., Samorapoompichit, P., Pickl, W. F., Sexl, V., Esterbauer, H., Schwarzinger, I., Sillaber, C., Maeda, H., Valent, P. (2008). Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 111: 2200-2210 [Abstract] [Full Text]
le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., Kuliczkowski, K., Hochhaus, A., Mahon, F.-X., Saglio, G., Gobbi, M., Kwong, Y.-L., Baccarani, M., Hughes, T., Martinelli, G., Radich, J. P., Zheng, M., Shou, Y., Kantarjian, H. (2008). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111: 1834-1839 [Abstract] [Full Text]
Konig, H., Holyoake, T. L., Bhatia, R. (2008). Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111: 2329-2338 [Abstract] [Full Text]
Garcia, A. A. (2008). Small Molecules: Big Changes in the Cancer Treatment Paradigm. Journal of Pharmacy Practice 21: 17-35 [Abstract]
Yanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Nishii, K., Ueda, Y., Takeuchi, M., Miyawaki, S., Maruta, A., Narimatsu, H., Miyazaki, Y., Ohtake, S., Jinnai, I., Matsuo, K., Naoe, T., Ohno, R., for the Japan Adult Leukemia Study Group, (2008). Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. haematol 93: 287-290 [Abstract] [Full Text]
Marshall, H. M, Hammond, J. M (2008). Treatment Options in Imatinib-Resistant Chronic Myelogenous Leukemia. The Annals of Pharmacotherapy 42: 259-264 [Abstract] [Full Text]
Duncan, E. A., Goetz, C. A., Stein, S. J., Mayo, K. J., Skaggs, B. J., Ziegelbauer, K., Sawyers, C. L., Baldwin, A. S. (2008). I{kappa}B kinase {beta} inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Molecular Cancer Therapeutics 7: 391-397 [Abstract] [Full Text]
Schade, A. E., Schieven, G. L., Townsend, R., Jankowska, A. M., Susulic, V., Zhang, R., Szpurka, H., Maciejewski, J. P. (2008). Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 111: 1366-1377 [Abstract] [Full Text]
McLaughlin, J., Cheng, D., Singer, O., Lukacs, R. U., Radu, C. G., Verma, I. M., Witte, O. N. (2007). Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc. Natl. Acad. Sci. USA 104: 20501-20506 [Abstract] [Full Text]
Kopetz, S., Shah, A. N., Gallick, G. E. (2007). Src Continues Aging: Current and Future Clinical Directions. Clin. Cancer Res. 13: 7232-7236 [Abstract] [Full Text]
Fausel, C. (2007). Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm 64: S9-S15 [Abstract] [Full Text]
Frame, D. (2007). New strategies in controlling drug resistance in chronic myeloid leukemia. Am J Health Syst Pharm 64: S16-S21 [Abstract] [Full Text]
Schnipper, L. E. (2007). Update in Oncology. ANN INTERN MED 147: 775-782 [Full Text]
Burmeister, T., Schwartz, S., Taubald, A., Jost, E., Lipp, T., Schneller, F., Diedrich, H., Thomssen, H., Mey, U. J.M., Eucker, J., Rieder, H., Gokbuget, N., Hoelzer, D., Thiel, E. (2007). Atypical BCR-ABL mRNA transcripts in adult Acute lymphoblastic leukemia. haematol 92: 1699-1702 [Abstract] [Full Text]
Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Kocher, T., Superti-Furga, G. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063 [Abstract] [Full Text]
Cortes, J., Jabbour, E., Kantarjian, H., Yin, C. C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., Wierda, W. G., Jones, D. (2007). Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110: 4005-4011 [Abstract] [Full Text]
Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., Bhatia, R., Cervantes, F., Haque, A., Shou, Y., Resta, D. J., Weitzman, A., Hochhaus, A., le Coutre, P. (2007). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3540-3546 [Abstract] [Full Text]
Bergeron, A., Rea, D., Levy, V., Picard, C., Meignin, V., Tamburini, J., Bruzzoni-Giovanelli, H., Calvo, F., Tazi, A., Rousselot, P. (2007). Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Series. Am. J. Respir. Crit. Care Med. 176: 814-818 [Abstract] [Full Text]
Press, R. D., Galderisi, C., Yang, R., Rempfer, C., Willis, S. G., Mauro, M. J., Druker, B. J., Deininger, M. W.N. (2007). A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response. Clin. Cancer Res. 13: 6136-6143 [Abstract] [Full Text]
Goldman, J. M. (2007). How I treat chronic myeloid leukemia in the imatinib era. Blood 110: 2828-2837 [Abstract] [Full Text]
Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A. M., Gollerkeri, A., Coutre, S. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110: 2309-2315 [Abstract] [Full Text]
O'Hare, T., Eide, C. A., Deininger, M. W. N. (2007). Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249 [Abstract] [Full Text]
Shah, N. P. (2007). Progressive Thoughts about Progressive Disease. Clin. Cancer Res. 13: 5229-5231 [Full Text]
Williams, R. T., den Besten, W., Sherr, C. J. (2007). Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 21: 2283-2287 [Abstract] [Full Text]
Quintas-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R., Cortes, J. (2007). Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. JCO 25: 3908-3914 [Abstract] [Full Text]
Modugno, M., Casale, E., Soncini, C., Rosettani, P., Colombo, R., Lupi, R., Rusconi, L., Fancelli, D., Carpinelli, P., Cameron, A. D., Isacchi, A., Moll, J. (2007). Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358. Cancer Res. 67: 7987-7990 [Abstract] [Full Text]
Nicolini, F. E., Hayette, S., Corm, S., Bachy, E., Bories, D., Tulliez, M., Guilhot, F., Legros, L., Maloisel, F., Kiladjian, J.-J., Mahon, F.-X., Le, Q.-H., Michallet, M., Roche-Lestienne, C., Preudhomme, C. (2007). Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. haematol 92: 1238-1241 [Abstract] [Full Text]
Rahmani, M., Nguyen, T. K., Dent, P., Grant, S. (2007). The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation. Mol. Pharmacol. 72: 788-795 [Abstract] [Full Text]
Guo, T., Agaram, N. P., Wong, G. C., Hom, G., D'Adamo, D., Maki, R. G., Schwartz, G. K., Veach, D., Clarkson, B. D., Singer, S., DeMatteo, R. P., Besmer, P., Antonescu, C. R. (2007). Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor. Clin. Cancer Res. 13: 4874-4881 [Abstract] [Full Text]
Hantschel, O., Rix, U., Schmidt, U., Burckstummer, T., Kneidinger, M., Schutze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., Superti-Furga, G. (2007). The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl. Acad. Sci. USA 104: 13283-13288 [Abstract] [Full Text]
Schiffer, C. A. (2007). BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. NEJM 357: 258-265 [Full Text]
Johnson, F. M., Saigal, B., Tran, H., Donato, N. J. (2007). Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects. Clin. Cancer Res. 13: 4233-4244 [Abstract] [Full Text]
Peng, C., Brain, J., Hu, Y., Goodrich, A., Kong, L., Grayzel, D., Pak, R., Read, M., Li, S. (2007). Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110: 678-685 [Abstract] [Full Text]
Pfeifer, H., Wassmann, B., Pavlova, A., Wunderle, L., Oldenburg, J., Binckebanck, A., Lange, T., Hochhaus, A., Wystub, S., Bruck, P., Hoelzer, D., Ottmann, O. G. (2007). Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110: 727-734 [Abstract] [Full Text]
Tsao, A. S., He, D., Saigal, B., Liu, S., Lee, J. J., Bakkannagari, S., Ordonez, N. G., Hong, W. K., Wistuba, I., Johnson, F. M. (2007). Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Molecular Cancer Therapeutics 6: 1962-1972 [Abstract] [Full Text]
Carew, J. S., Nawrocki, S. T., Kahue, C. N., Zhang, H., Yang, C., Chung, L., Houghton, J. A., Huang, P., Giles, F. J., Cleveland, J. L. (2007). Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110: 313-322 [Abstract] [Full Text]
Hehlmann, R., Berger, U., Pfirrmann, M., Heimpel, H., Hochhaus, A., Hasford, J., Kolb, H.-J., Lahaye, T., Maywald, O., Reiter, A., Hossfeld, D. K., Huber, C., Loffler, H., Pralle, H., Queisser, W., Tobler, A., Nerl, C., Solenthaler, M., Goebeler, M. E., Griesshammer, M., Fischer, T., Kremers, S., Eimermacher, H., Pfreundschuh, M., Hirschmann, W.-D., Lechner, K., Wassmann, B., Falge, C., Kirchner, H. H., Gratwohl, A., for the Schweizerische Arbeitsgemeinschaft fur Kli, (2007). Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109: 4686-4692 [Abstract] [Full Text]
O'Brien, S. (2007). Dasatinib in accelerated phase. Blood 109: 4110-4110 [Full Text]
Guilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., de Souza, C. A., Lipton, J. H., Hochhaus, A., Heim, D., Larson, R. A., Branford, S., Muller, M. C., Agarwal, P., Gollerkeri, A., Talpaz, M. (2007). Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109: 4143-4150 [Abstract] [Full Text]
Jiang, X., Saw, K. M., Eaves, A., Eaves, C. (2007). Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells. JNCI J Natl Cancer Inst 99: 680-693 [Abstract] [Full Text]
Spinelli, O., Peruta, B., Tosi, M., Guerini, V., Salvi, A., Zanotti, M. C., Oldani, E., Grassi, A., Intermesoli, T., Mico, C., Rossi, G., Fabris, P., Lambertenghi-Deliliers, G., Angelucci, E., Barbui, T., Bassan, R., Rambaldi, A. (2007). Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. haematol 92: 612-618 [Abstract] [Full Text]
Goodin, S. (2007). Oral chemotherapeutic agents: Understanding mechanisms of action and drug interactions. Am J Health Syst Pharm 64: S15-S24 [Abstract] [Full Text]
Nguyen, T. K., Rahmani, M., Harada, H., Dent, P., Grant, S. (2007). MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 109: 4006-4015 [Abstract] [Full Text]
Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., Ottmann, O., Shah, N., Erben, P., Branford, S., Agarwal, P., Gollerkeri, A., Baccarani, M. (2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109: 3207-3213 [Abstract] [Full Text]
Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.-A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., Moore, N., Molimard, M., Mahon, F.-X. (2007). Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109: 3496-3499 [Abstract] [Full Text]
Soverini, S., Iacobucci, I., Baccarani, M., Martinelli, G. (2007). Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. haematol 92: 437-439 [Full Text]
Van Etten, R. A. (2007). Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J. Exp. Med. 204: 461-465 [Abstract] [Full Text]
Perrotti, D., Neviani, P. (2007). From mRNA Metabolism to Cancer Therapy: Chronic Myelogenous Leukemia Shows the Way. Clin. Cancer Res. 13: 1638-1642 [Abstract] [Full Text]
Rowe, J. M. (2007). Closing the gap in CML. Blood 109: 2271-2271 [Full Text]
Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., Silver, R. T., Stone, R. M., Hughes, T. P., Muller, M. C., Ezzeddine, R., Countouriotis, A. M., Shah, N. P. (2007). Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109: 2303-2309 [Abstract] [Full Text]
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., Clark, E. (2007). Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection. Cancer Res. 67: 2226-2238 [Abstract] [Full Text]
Soverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Paolini, S., Rondoni, M., Piccaluga, P. P., Palandri, F., Giannoulia, P., Marzocchi, G., Luatti, S., Testoni, N., Iacobucci, I., Cilloni, D., Saglio, G., Baccarani, M., Martinelli, G. (2007). Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. haematol 92: 401-404 [Abstract] [Full Text]
Wang, Y., Cai, D., Brendel, C., Barett, C., Erben, P., Manley, P. W., Hochhaus, A., Neubauer, A., Burchert, A. (2007). Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109: 2147-2155 [Abstract] [Full Text]
Kantarjian, H. M., Giles, F., Quintas-Cardama, A., Cortes, J. (2007). Important Therapeutic Targets in Chronic Myelogenous Leukemia. Clin. Cancer Res. 13: 1089-1097 [Abstract] [Full Text]
Lerma, E. I., Nguyen, V.-A., Wang, T., Tipping, A., Melo, J. V., Kufe, D., Austin, D. J., Deisseroth, A. (2007). Novel compounds with antiproliferative activity against imatinib-resistant cell lines. Molecular Cancer Therapeutics 6: 655-666 [Abstract] [Full Text]
Martinelli, G., Soverini, S., Iacobucci, I., Baccarani, M. (2007). MK-0457: a light at the end of the tunnel?. Blood 109: 396-397 [Full Text]
Giles, F. J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., Freedman, S. J. (2007). MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109: 500-502 [Abstract] [Full Text]
Quintas-Cardama, A., Kantarjian, H., Jones, D., Nicaise, C., O'Brien, S., Giles, F., Talpaz, M., Cortes, J. (2007). Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109: 497-499 [Abstract] [Full Text]
Ozols, R. F., Herbst, R. S., Colson, Y. L., Gralow, J., Bonner, J., Curran, W. J. Jr, Eisenberg, B. L., Ganz, P. A., Kramer, B. S., Kris, M. G., Markman, M., Mayer, R. J., Raghavan, D., Reaman, G. H., Sawaya, R., Schilsky, R. L., Schuchter, L. M., Sweetenham, J. W., Vahdat, L. T., Winn, R. J. (2007). Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening--A Report From the American Society of Clinical Oncology. JCO 25: 146-162 [Abstract] [Full Text]
Lierman, E., Lahortiga, I., Van Miegroet, H., Mentens, N., Marynen, P., Cools, J. (2007). The ability of sorafenib to inhibit oncogenic PDGFR{beta} and FLT3 mutants and overcome resistance to other small molecule inhibitors. haematol 92: 27-34 [Abstract] [Full Text]
Shah, N. P. (2007). Medical Management of CML. ASH Education Book 2007: 371-375 [Abstract] [Full Text]
Thomas, D. A. (2007). Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges. ASH Education Book 2007: 435-443 [Abstract] [Full Text]
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., Cortes, J. (2006). New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance. ANN INTERN MED 145: 913-923 [Abstract] [Full Text]
Skaggs, B. J., Gorre, M. E., Ryvkin, A., Burgess, M. R., Xie, Y., Han, Y., Komisopoulou, E., Brown, L. M., Loo, J. A., Landaw, E. M., Sawyers, C. L., Graeber, T. G. (2006). Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc. Natl. Acad. Sci. USA 103: 19466-19471 [Abstract] [Full Text]
Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E., Radaelli, F., Ciccone, F., Tiribelli, M., di Lorenzo, R., Caracciolo, C., Izzo, B., Pane, F., Saglio, G., Baccarani, M., Martinelli, G., on behalf of the GIMEMA Working Party on Chronic M, (2006). Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12: 7374-7379 [Abstract] [Full Text]
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W.N., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J. L., Radich, J. P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., Larson, R. A., the IRIS Investigators, (2006). Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. NEJM 355: 2408-2417 [Abstract] [Full Text]
Chuah, C., Lim, T. H., Lim, A. S. T., Tien, S. L., Lim, C. H., Soong, R., Lee, F., Linn, Y. C., Goh, Y. T., Cheah, F. K., Loh, A. H. L. (2006). Dasatinib Induces a Response in Malignant Thymoma. JCO 24: e56-e58 [Full Text]
Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., Andreoni, F., Scapozza, L., Formelli, F., Gambacorti-Passerini, C. (2006). In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Res. 66: 11314-11322 [Abstract] [Full Text]
Fausel, C. A. (2006). Novel treatment strategies for chronic myeloid leukemia.. Am J Health Syst Pharm 63: S15-S20 [Abstract] [Full Text]
Soverini, S., Martinelli, G., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Paolini, S., Rondoni, M., Piccaluga, P. P., Palandri, F., Giannoulia, P., Marzocchi, G., Luatti, S., Testoni, N., Iacobucci, I., Cilloni, D., Saglio, G., Baccarani, M. (2006). Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia. JCO 24: e51-e52 [Full Text]
Hu, Y., Swerdlow, S., Duffy, T. M., Weinmann, R., Lee, F. Y., Li, S. (2006). Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. USA 103: 16870-16875 [Abstract] [Full Text]

Comments and questions? Please contact us.